KYE Pharmaceuticals Inc. today announced it has submitted a New Drug Submission (NDS) to Health Canada for the regulatory review and approval of Accrufer® (ferric maltol). If approved, Accrufer® would be the first prescription only oral iron therapy approved by Health Canada and marketing approval for Accrufer® is expected to be during the first half…

eTurboNews amanqaku ngababhalisi kuphela. Umrhumo ngu fREE.
Ababhalisi bangena apha Cofa apha ukuze ubhalise FREE

INTO ONOKUYITHATHA KWELI NQAKU:

namhlanje ibhengeze ukuba ingenise i-New Drug Submission (NDS) kwi-Health Canada ukuze kuhlaziywe ukulawulwa kunye nokuvunywa kwe-Accrufer® (i-ferric maltol).
If approved, Accrufer® would be the first prescription only oral iron therapy approved by Health Canada and marketing approval for Accrufer® is expected to be during the first half….
eTurboNews amanqaku ngababhalisi kuphela.